Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Beigene Ltd (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
BGNE
Nasdaq
2834
https://www.beigene.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Beigene Ltd (ADR)
20 Countries with the Highest Rates of Stomach Cancer in the World
- Apr 25th, 2024 12:53 pm
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
- Apr 24th, 2024 8:01 pm
With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners
- Apr 23rd, 2024 1:49 pm
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- Apr 23rd, 2024 10:00 am
Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week
- Mar 27th, 2024 12:48 pm
30 Biggest Biotechnology Companies in the World
- Mar 17th, 2024 12:50 pm
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- Mar 14th, 2024 8:28 pm
UPDATE 1-US FDA approves BeiGene's esophageal cancer therapy
- Mar 14th, 2024 6:54 pm
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- Mar 13th, 2024 12:00 pm
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
- Mar 7th, 2024 10:19 pm
UPDATE 2-US FDA approves expanded use of BeiGene's blood cancer drug
- Mar 7th, 2024 8:39 pm
Q4 2023 Zymeworks Inc Earnings Call
- Mar 7th, 2024 6:10 pm
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
- Mar 6th, 2024 11:00 am
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- Feb 29th, 2024 3:00 pm
BeiGene Full Year 2023 Earnings: Beats Expectations
- Feb 28th, 2024 6:49 pm
BeiGene to Present at Upcoming Investor Conferences
- Feb 28th, 2024 1:05 pm
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
- Feb 27th, 2024 11:00 am
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight
- Feb 27th, 2024 5:05 am
BeiGene Ltd (BGNE) Reports Substantial Revenue Growth and Pipeline Progress in Q4 and Full Year 2023
- Feb 26th, 2024 11:32 am
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Feb 26th, 2024 11:00 am
Scroll